- Home
- ASPI vs SCTX Comparison
ASPI vs SCTX Comparison
Compare ASPI & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASPI | SCTX |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.5M | 536.5M |
| IPO Year | 2022 | 2026 |
Fundamental Metrics
Financial Performance| Metric | ASPI | SCTX |
|---|---|---|
| Price | $1.89 | $17.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $13.00 | ★ $57.00 |
| AVG Volume (30 Days) | ★ 4.2M | 378.6K |
| Earning Date | 11-18-2026 | 11-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $23,849,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $189.67 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 475.48 | N/A |
| 52 Week Low | $1.80 | $13.50 |
| 52 Week High | $9.38 | $39.60 |
Technical Indicators
Market Signals| Indicator | ASPI | SCTX |
|---|---|---|
| Relative Strength Index (RSI) | 29.73 | 39.86 |
| Support Level | N/A | $13.50 |
| Resistance Level | $3.06 | $22.07 |
| Average True Range (ATR) | 0.17 | 1.97 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 3.37 | 24.94 |
Price Performance
Historical ComparisonAbout ASPI ASP Isotopes Inc.
ASP Isotopes Inc is a materials company focused on producing and commercializing enriched isotopes for the nuclear medicine, healthcare, green energy, and quantum computing industries. Currently, the company has three operating segments: (i) nuclear fuels, (ii) specialist isotopes and related services, and (iii) construction services. Using proprietary technology-the Aerodynamic Separation Process (ASP)-the company enriches isotopes in South Africa, targeting high-value, low-volume markets to reduce reliance on foreign supply chains. Geographically, the company operates in South Africa, Hong Kong and United States generating key revenue from the Hong Kong region.
About SCTX Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.